Liver and Bile

Hepatology. 2022;76(4):1180–9

Bruce MG, Bruden D, Hurlburt D, Morris J, Bressler S, Thompson G, Lecy D, Rudolph K, Bulkow L, Hennessy T, Simons BC, Weng MK, Nelson N, McMahon BJ

Protection and antibody levels 35 years after primary series with hepatitis B vaccine and response to a booster dose

Background and aims: The duration of protection from hepatitis B vaccination in children and adults is not known. In 1981, the authors used 3 doses of plasma-derived hepatitis B vaccine to immunize a cohort of 1578 Alaska Native adults and children from 15 Alaska communities who were ≥ 6 months old.
Approach and results: They tested persons for antibody to hepatitis B surface antigen (anti-HBs) levels 35 years after receiving the primary series. Those with levels < 10 mIU/ml received 1 booster dose of recombinant hepatitis B vaccine 2–4 weeks later and were then evaluated on the basis of anti-HBs measurements 30 days postbooster. Among the 320 recruited, 112 persons had not participated in the 22- or 30-year follow-up study (group 1), and 208 persons had participated but were not given an HBV booster dose (group 2). Among the 112 persons in group 1 who responded to the original primary series, 53 (47.3%) had an anti-HBs level ≥ 10 mIU/ml. Among group 1, 73.7% of persons (28/38) available for a booster dose responded to it with an anti-HBs level ≥ 10 mIU/ml at 30 days. Initial anti-HBs level after the primary series was correlated with higher anti-HBs levels at 35 years. Among 8 persons who tested positive for antibody to hepatitis B core antigen, none tested positive for HBsAg or HBV DNA.

Conclusions: Based on anti-HBs level ≥ 10 mIU/ml at 35 years and a 73.7% booster dose response, it was estimated that 86% of participants had evidence of protection 35 years later. Booster doses are not needed in the general population at this time.

M.G. Bruce, M.D., Division of Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Infectious Diseases, Arctic Investigations Program, Centers for Disease Control and Prevention, Anchorage, AK, USA,

DOI: DOI: 10.1002/hep.32474

Back to overview

this could be of interest:

Ethylglucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease

J Hepatol. 2022;77(4):918–30

Severe acute autoimmune hepatitis: How to early predict who will not respond to corticosteroids and needs urgent liver transplantation?

Dig Liver Dis. 2022;54(12):1681–5

More articles on the topic